Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure.
Vandenhende MA, Bellecave P, Recordon-Pinson P, Reigadas S, Bidet Y, Bruyand M, Bonnet F, Lazaro E, Neau D, Fleury H, Dabis F, Morlat P, Masquelier B. Vandenhende MA, et al. Among authors: masquelier b. PLoS One. 2014 Jan 27;9(1):e86771. doi: 10.1371/journal.pone.0086771. eCollection 2014. PLoS One. 2014. PMID: 24475178 Free PMC article.
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B. da Silva D, et al. Among authors: masquelier b. J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12. J Antimicrob Chemother. 2010. PMID: 20388636
Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine. Masquelier B, et al. Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32. doi: 10.1128/AAC.46.9.2926-2932.2002. Antimicrob Agents Chemother. 2002. PMID: 12183249 Free PMC article. Clinical Trial.
HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs.
Fleury H, Recordon-Pinson P, Caumont A, Faure M, Roques P, Plantier JC, Couturier E, Dormont D, Masquelier B, Simon F; Agence Nationale de Recherche sur le SIDA AC11 Laboratory Network. Fleury H, et al. Among authors: masquelier b. AIDS Res Hum Retroviruses. 2003 Jan 1;19(1):41-7. doi: 10.1089/08892220360473952. AIDS Res Hum Retroviruses. 2003. PMID: 12596719
Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data.
Fleury HJ, Toni T, Lan NT, Hung PV, Deshpande A, Recordon-Pinson P, Boucher S, Lazaro E, Jauvin V, Lavignolle-Aurillac V, Lebel-Binay S, Cheret A, Masquelier B. Fleury HJ, et al. Among authors: masquelier b. AIDS Res Hum Retroviruses. 2006 Apr;22(4):357-66. doi: 10.1089/aid.2006.22.357. AIDS Res Hum Retroviruses. 2006. PMID: 16623640
227 results